Tabalumab

Drug Profile

Tabalumab

Alternative Names: Anti-BAFF MAb; Anti-BAFF monoclonal antibody; LY 2127399

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Multiple sclerosis; Renal failure; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 17 May 2018 Eli Lilly terminates the phase IIIb Illuminate-X trial for Systemic lupus erythematosus in USA, Austria, Hungary, Spain, Latvia, Bulgaria, Italy, the United Kingdom, Germany, and Croatia (NCT01488708)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2015 Eli Lilly terminates phase III trial in Systemic lupus erythematosus in USA, South Korea, Mexico and Puerto Rico due to lack of efficacy (NCT02041091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top